Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis | Zendy

Kelly Cristina Kato | Zendy; Eliane de Morais-Teixeira | Zendy; Arshad Islam | Zendy; M. Fatima Leite | Zendy; Cynthia Demicheli | Zendy; Whocely Victor de Castro | Zendy; José Dias Corrêa | Zendy; Ana Rabello | Zendy; Frédéric Frézard | Zendy

Open Access

Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis

Author(s) -

Kelly Cristina Kato,

Eliane de Morais-Teixeira,

Arshad Islam,

M. Fatima Leite,

Cynthia Demicheli,

Whocely Victor de Castro,

José Dias Corrêa,

Ana Rabello,

Frédéric Frézard

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00539-18

Subject(s) - meglumine antimoniate , meglumine , visceral leishmaniasis , drug , pharmacology , leishmaniasis , medicine , chemistry , immunology , magnetic resonance imaging , radiology

Progress toward the improvement of meglumine antimoniate (MA), commercially known as Glucantime, a highly effective but also toxic antileishmanial drug, has been hindered by the lack of knowledge and control of its chemical composition. Here, MA was manipulated chemically with the aim of achieving an orally effective drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research